

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 90451

Title: Prospective study of hepatitis B and D epidemiology and risk factors in Romania:

A 10-year update

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02861217 Position: Editorial Board Academic degree: MD, PhD

Professional title: Chief Doctor, Deputy Director

Reviewer's Country/Territory: Armenia

Author's Country/Territory: Romania

Manuscript submission date: 2023-12-06

Reviewer chosen by: Huo Liu

Reviewer accepted review: 2024-01-10 07:39

Reviewer performed review: 2024-01-14 19:17

Review time: 4 Days and 11 Hours

	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[Y] Grade A: Excellent [] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair
this manuscript	[] Grade D: No creativity or innovation



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 E-mail: office@baishideng.com https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y] Yes [] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Dear authors, Your manuscript could be published after minor revision by providing or clarifying some data. Please mentioned 1. which tests are used for checking anti-HDV immunoglobulin G antibodies by enzyme-linked immunosorbent assays? 2. which single and nested PCR tests (commercial?) are used for HDV RNA? 3. all variables using in multivariate multiple regression analysis in materials and methods 4. is there hypothesis explained higher proportion of female HBV/HDV co-infected compare to HBV-monoinfection, take into account high imprisonment and injecting drug use in HBV/HDV co-infected compare to HBV-monoinfection? 5. provide also percentage of HBV viremia was less than 20 IU/mL in HBV- monoinfection 6. is there more data on combination therapy of pegylated interferon-α and nucleos(t)ide analogues in patients with HBV/HDV coinfection: the simultaneous "dual" strategy, sequential combination "add-on" strategy, and "switch" strategy? 7. how can you explain, that 12.5% of patients are vaccinated against HBV in HBV/HDV co-infected and 15.6 HBV-monoinfection groups? 8. sexual contact with a partner positive for HBV/HCV/HDV means all tree infections simultaneously (coinfections) or two or even one off mentioned? 9.



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

hepatocellular carcinoma diagnosis and management standardized (national guidelines) in Romania? Thank you. Best regards,